Data for Viamet’s VT-1161 Presented at ICAAC 2014

Studies Demonstrate Additional Evidence of Broad-Spectrum Antifungal Activity

Phase 2b Trials Planned for VT-1161 in the Second Half of 2014

ICAAC 2014

RESEARCH TRIANGLE PARK, N.C.--()--Viamet Pharmaceuticals today reported that positive preclinical studies for VT-1161, the Company’s lead novel, oral antifungal compound were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), which was held from September 5-9, 2014, in Washington D.C. Overall, the data presented demonstrate additional evidence of the broad-spectrum antifungal activity of VT-1161. Viamet expects to begin Phase 2b clinical trials for VT-1161 in patients with recurrent vulvovaginal candidiasis (RVVC) and in patients with onychomycosis in the second half of 2014.

The VT-1161 studies were presented in two oral presentations and one poster presentation. The presentation titles and presenters were as follows:

Presentation Title: The Clinical Antifungal Agent VT-1161 is Orally Efficacious Against Fluconazole-Resistant Isolates in a Murine Model of C. albicans Vaginitis
Presented by Edward Garvey, Ph.D., Director of Anti-Infective Biology, Viamet Pharmaceuticals

Presentation Title: The Fungal Cyp51 Inhibitor VT-1161 Demonstrates In Vitro Synergy with Tacrolimus Against Aspergillus spp. and Members of the Order Mucorales
Presented by Nathan Wiederhold, Pharm.D., Associate Professor and Director, Fungus Testing Laboratory, University of Texas Health Science Center, San Antonio

Presentation Title: VT-1161, a Novel Fungal CYP51 Inhibitor, Improved Survival in Murine Models of Coccidioidomycosis
Lead author John Galgiani, M.D., Professor and Director, Valley Fever Center for Excellence, University of Arizona

For additional detail on data presented at ICAAC, please go to http://www.viamet.com/products/vt-1161

About VT-1161

VT-1161 is a potent and selective, orally available inhibitor of fungal CYP51. In in vitro and in vivo studies, VT-1161 has demonstrated broad spectrum activity against Candida species, a broad family of fungi that resemble yeasts and frequently cause infections in humans. In in vitro and in vivo studies, VT-1161 has also demonstrated broad spectrum activity against dermatophytes, a broad family of fungi that frequently cause skin, nail and hair infections. Based on our research to date, we believe that VT-1161 is highly active against most species of Candida, the causative agent in RVVC, including Candida glabrata and fluconazole-resistant strains of Candida. Also, based on our research to date, we believe VT-1161 is highly active against Trichophyton rubrum and Trichophyton mentagrophytes, the two most common dermatophyte species that cause onychomycosis. As VT-1161 is highly selective for fungal CYP51, we believe that it may avoid the side effects that limit the use of commonly prescribed antifungals, including fluconazole, itraconazole, posaconazole, terbinafine and voriconazole.

About Viamet (www.viamet.com)

Viamet is a biopharmaceutical company focused on the discovery, development and commercialization of novel antifungal agents based on our proprietary metalloenzyme medicinal chemistry platform, which we call our Metallophile® Technology. Metalloenzymes are enzymes that contain a metal, such as iron, zinc or copper, that is linked to the enzyme’s protein component. We are using our platform to design drugs that we expect to have greater selectivity, fewer side effects and improved potency compared to currently available antifungal agents. Our lead product candidate, VT-1161, is an oral agent that we are developing for the treatment of recurrent vulvovaginal candidiasis, or RVVC, a highly prevalent mucosal infection for which there are no approved therapies in the United States, and onychomycosis, a very common fungal infection of the nail for which current treatments are suboptimal with respect to safety, tolerability and efficacy.

This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet’s business and VT-1161, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success.

Contacts

Viamet Pharmaceuticals, Inc.
Rich Katz, M.D., Chief Business and Financial Officer
+919-467-8539 ext. 316

Contacts

Viamet Pharmaceuticals, Inc.
Rich Katz, M.D., Chief Business and Financial Officer
+919-467-8539 ext. 316